Johnson & Johnson 340B Rebate Model Threat Halted Due to Advocates Like the North Carolina Community Health Center Association.

On September 30, 2024 Johnson & Johnson (J&J) announced it was ending its plans to implement a 340B rebate model for two of its drugs, Stelara and Xarelto. The immediate halt to the rebate model was prompted by the Health Resources and Services Administration’s (HRSA) September 27 letter threatening to terminate J&J’s participation in the…

Big Pharma profits off addiction, 340B supports recovery.

Damien Center 340B Ad Campaign Spreads Mental Health and Substance Use Awareness

PRESS RELEASE – September 24, 2024 Damien Center, Indiana’s oldest and largest AIDS service organization, partnered with CV340B to execute an eight-week digital ad campaign to educate the Indiana community about the federal 340B program through CV340B’s Digital Engagement Campaign Together with 340B. The two-part campaign, which wrapped up last month, featured ads that educated…

340B Could Have Saved My Mother’s Life

A 340B Program Assistant Director shares how the federal 340B program could have saved the lives of her mother and other low-income Medicaid patients. by Kelli Pardee, MBA, CPhT 340B Program Assistant Director, Great Lakes Bay Health Centers May 2024   My name is Kelli Pardee, and I am a 340B Program Assistant Director at…

Don't let Pharma increase your family's taxes

Community Voices for 340B’s National Digital Ad Campaign Spreads the Word: Don’t Let Big Pharma Raise Your Taxes

PRESS RELEASE – May 15, 2024 The federal 340B Program stretches the limited federal resources given to non-profit healthcare providers without raising taxes. This spring, CV340B set out to tell the truth about 340B and defend the program from ongoing attacks by the drug industry. We started digital ad campaigns in Virginia and West Virginia,…

CV340B Responds to Second Senate RFI on 340B

FOR IMMEDIATE RELEASE- (Washington D.C. –  April 24, 2024) On April 1, 2024  Community Voices for 340B submitted a response to Senators Thune, Stabenow, Capito, Baldwin, Moran, and Cardin’s second request for information on the 340B Drug Discount Program. In it’s response CV340B conducted independent analysis of the publicly available HRSA audit reports finding that…